Wistar scientists have combined a promising cancer therapy with a molecule that targets tumors to treat cancer more effectively. The new approach could be a way to deliver treatment directly to tumors at higher doses, while reducing side effects in healthy tissue.
An Aurora kinase A (AURKA) inhibitor is viewed as a lethal synthetic molecule in cancer therapy, but the problem is you can’t dose it high enough, because then it starts to spill over and target normal cells, causing toxicity. By using this cancer-targeting approach, we can direct this molecule, which is already in clinical use, to cancer cells, increasing its exposure in the tumor itself.”
Joseph Salvino, Ph.D., coauthor
Salvino is professor in the Molecular and Cellular Oncogenesis…